South Korea’s Inventage Lab Inc. announced on Friday that it has signed a joint development agreement with Yuhan Corp. for a long-acting injectable for the treatment of obesity and diabetes.
Inventage Lab is developing a pipeline of differentiated long-acting injectables using its proprietary platform technology IVL-DrugFluidic.
Yuhan Corp. possesses business development capabilities and achievements in clinical development alongside marketing expertise.
Both companies anticipate mutual synergies in the field of obesity and diabetes treatment through this agreement.
Under the latest contract, Inventage Lab, leveraging its cumulative capabilities in long-acting injectable development, will handle formulation optimization, initial development, and manufacturing.
Yuhan Corp., with its excellent clinical development capabilities, will take charge of late-stage development and commercialization, jointly pursuing the maximization of product value.
Inventage Lab is conducting preclinical trials for "IVL3021," a one-month long-acting injectable based on semaglutide for obesity treatment. Recently, stable formulation research results were presented at an international conference.
Semaglutide is the active ingredient in Novo Nordisk's obesity treatment Wegovy, demonstrating a 14.9% weight loss effect over a year and efficacy in cardiovascular diseases.
Write to Ye-Na Kim at
yena@hankyung.com
